ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

INTRODUCTION: Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies have shown that the effect on achieving (clinical)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dirikgil, Ebru, van Leeuwen, Jolijn R, van Dam, Laura S, Bredewold, Obbo W, Ray, Argho, Jonker, Jacqueline T, Soonawala, Darius, Remmelts, Hilde H F, van Dam, Bastiaan, Bos, Willem Jan, van Kooten, Cees, Rotmans, Joris, Rabelink, Ton, Teng, Y K Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494556/
https://www.ncbi.nlm.nih.gov/pubmed/36130755
http://dx.doi.org/10.1136/bmjopen-2022-061339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494556/
https://www.ncbi.nlm.nih.gov/pubmed/36130755
http://dx.doi.org/10.1136/bmjopen-2022-061339

Ejemplares similares